Davis Polk advised J.P. Morgan Securities LLC as sole book-running manager of a $70 million SEC-registered offering of 17,500,000 shares of common stock of Dynavax Technologies Corporation. The common stock of Dynavax is listed on Nasdaq under the symbol “DVAX.”

Headquartered in Berkeley, California, Dynavax is a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases. Its lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide higher and earlier protection with fewer doses than currently licensed vaccines.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Meng Lai, Steve Valenzuela and Emily Roberts. The intellectual property team included associates Emma Maconick and Bruce Rose-Innes. The tax team included partner Po Sit and associate Catherine Paskoff Chang. Haniya H. Mir was the legal assistant on the transaction. Members of the Davis Polk team are based in the Menlo Park and New York offices.



Related Posts:

Leave a Reply